Neurocrine Biosciences Announces FDA Appro...
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes ONGENT...
Since 2004, brands have counted on Cision’s MultiVu to create and distribute their important news and marketing content to the world.
Let's talkSearch our recent client collaborations below: